Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 17/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13409355 | 0.75 | IDO1 (0.50) | IRAK4IDO1 | |
| SCHEMBL2621791 | 0.75 | GAK (0.46) | IRAK4 | |
| SCHEMBL26184474 | 0.73 | FGFR2 (0.43) | FGFR2 | |
| SCHEMBL25826719 | 0.72 | DOT1L (0.48) | IRAK4 | |
| SCHEMBL17132541 | 0.71 | FGFR2 (0.54) | FGFR2 | |
| SCHEMBL12282776 | 0.71 | MAPT (0.47) | IRAK4 | |
| SCHEMBL14916090 | 0.69 | FGFR2 (0.46) | IRAK4FGFR2 | |
| SCHEMBL25826717 | 0.69 | IP6K1 (0.48) | IRAK4 | |
| SCHEMBL25826718 | 0.69 | IP6K1 (0.45) | IRAK4 | |
| SCHEMBL25826632 | 0.68 | CCNC (0.46) | IRAK4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | IRAK4 1748/4885FGFR2 1262/4885IDO1 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.